Gosselies, Belgium and Utrecht, The Netherlands, 21 December 2021 – Thuja Capital is pleased to announce that EsoBiotec, the Belgian company developing accessible next generation cell-based cancer treatments, has expanded its investor base through an investment by UCB Ventures. With this additional investor, the company has now raised EUR 6M from investors in total, on top of EUR 3M in non-dilutive Walloon government funding. Emmanuel Lacroix, partner at UCB Ventures, has joined the board.
Michel Briejer, board member of EsoBiotec and Managing Partner at Thuja Capital commented:
We are extremely pleased with the addition of UCB Ventures and with Emmanuel joining the board in particular, as he brings a lot of knowhow and network to EsoBiotec. We consider it also as a confirmation of the potential of EsoBiotec.